Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype: early-phase trial registry
2 of 2 indexed Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #7,188 of 28,707 conditions by registered trial count.
2 US clinical trials · 2 currently recruiting · #7,188 of 28,707 conditions by registered trial count
Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype: 2 US clinical trials tracked, 2 recruiting.
Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype is the subject of 2 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Orbus Therapeutics, running 1 of these trials.
Enrollment posture brief
Registry condition glioblastoma-idh-isocitrate-dehydrogenase-wildtype
OPEN 2 | RECR 100% | LATE 0 | EARLY 2 | RANK #7188 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)
Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype lists 2 open slots (100% of 2 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype is recruiting above its size-band peers.
2 of 2 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
2 total, page 1 of 1
A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
Debiopharm International
NCT05765812
Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma
Orbus Therapeutics
NCT05879367
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype page
2 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Orbus Therapeutics sponsors the most Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype trials on record, review their full trial history before evaluating a specific study. See Orbus Therapeutics's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype condition card totals 2 registered trials; most-linked intervention Temozolomide; top US site state Utah. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.